Prolonged Cytopenias After First-Line Treatment With Venetoclax and Hypomethylating Agent in Newly Diagnosed AML/MDS-IB

被引：0
|
作者：
Smalinskaite, Tautvile [1 ,2 ]
Kevlicius, Lukas [1 ,2 ]
Vaitekenaite, Vilmante [1 ,2 ]
Daukelaite, Guoda [1 ,2 ]
Griskevicius, Laimonas [1 ,2 ]
Zucenka, Andrius [1 ,2 ]
机构：
[1] Vilnius Univ Hosp Santaros Klin, Hematol Oncol & Transfus Med Ctr, Vilnius, Lithuania
[2] Vilnius Univ, Inst Clin Med, Dept Hematol & Oncol, Vilnius, Lithuania
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
AML; MDS; venetoclax; HMA; neutropenia;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-700
引用
收藏
页码：S332 / S332
页数：1
相关论文
共 50 条
  • [1] Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US
    Vachhani, Pankit
    Flahavan, Evelyn M.
    Xu, Tao
    Ma, Esprit
    Montez, Melissa
    Gershon, Anda
    Onishi, Maika
    Jin, Huan
    Ku, Grace
    Flores, Brannon
    Bui, Cat N.
    Abbas, Jonathan A.
    Donnellan, William
    ONCOLOGIST, 2022, 27 (11): : 907 - 918
  • [2] Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax
    Chen, Evan C.
    Liu, Yiwen
    Harris, Courtney E.
    Winer, Eric S.
    Wadleigh, Martha
    Lane, Andrew A.
    Vedula, Rahul S.
    Lindsley, R. Coleman
    Copson, Kevin M.
    Charles, Anne
    Marty, Francisco
    Neuberg, Donna
    DeAngelo, Daniel J.
    Stone, Richard M.
    Luskin, Marlise R.
    Issa, Nicolas C.
    Garcia, Jacqueline S.
    LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1934 - 1941
  • [3] First-Line Venetoclax and a Hypomethylating Agent or Conventional Chemotherapy in Older Adults with IDH-Mutated AML
    Bouligny, Ian
    Murray, Graeme
    Ho, Thuy
    Gor, Juhi
    Zacholski, Kyle
    Wages, Nolan
    Grant, Steven
    Maher, Keri
    BLOOD, 2023, 142
  • [4] Antifungal Prophylaxis: Impact on Outcomes of Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax
    Chen, Evan C.
    Liu, Yiwen
    Winer, Eric S.
    Luskin, Marlise R.
    Wadleigh, Martha
    Lane, Andrew A.
    Vedula, Rahul S.
    Lindsley, Coleman
    Copson, Kevin
    Charles, Anne
    Neuberg, Donna S.
    Issa, Nicolas C.
    DeAngelo, Daniel J.
    Stone, Richard M.
    Garcia, Jacqueline S.
    BLOOD, 2021, 138
  • [5] A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
    Short, Nicholas J.
    Muftuoglu, Muharrem
    Ong, Faustine
    Nasr, Lewis
    Macaron, Walid
    Montalban-Bravo, Guillermo
    Alvarado, Yesid
    Basyal, Mahesh
    Daver, Naval
    Dinardo, Courtney D.
    Borthakur, Gautam
    Jain, Nitin
    Ohanian, Maro
    Jabbour, Elias
    Issa, Ghayas C.
    Qiao, Wei
    Huang, Xuelin
    Kanagal-Shamanna, Rashmi
    Patel, Keyur P.
    Bose, Prithviraj
    Ravandi, Farhad
    Delumpa, Ricardo
    Abramova, Regina
    Garcia-Manero, Guillermo
    Andreeff, Michael
    Cortes, Jorge
    Kantarjian, Hagop
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [6] Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS)
    Cogle, Christopher R.
    Mukherjee, Sudipto
    Lawrence, Moira E.
    McKearn, Thomas J.
    Percy, Rita
    Petrone, Michael E.
    Megaffin, Scott
    Anene, Ayanna M.
    Ortendahl, Jesse
    Romanus, Dorothy
    Bentley, Tanya G. K.
    BLOOD, 2014, 124 (21)
  • [7] A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
    Nicholas J. Short
    Muharrem Muftuoglu
    Faustine Ong
    Lewis Nasr
    Walid Macaron
    Guillermo Montalban-Bravo
    Yesid Alvarado
    Mahesh Basyal
    Naval Daver
    Courtney D. Dinardo
    Gautam Borthakur
    Nitin Jain
    Maro Ohanian
    Elias Jabbour
    Ghayas C. Issa
    Wei Qiao
    Xuelin Huang
    Rashmi Kanagal-Shamanna
    Keyur P. Patel
    Prithviraj Bose
    Farhad Ravandi
    Ricardo Delumpa
    Regina Abramova
    Guillermo Garcia-Manero
    Michael Andreeff
    Jorge Cortes
    Hagop Kantarjian
    Journal of Hematology & Oncology, 16
  • [8] Does time to treatment matter with venetoclax as first-line treatment for AML?
    Baden, D.
    Wolgast, N.
    Pohlmann, A.
    Steinhaeuser, S.
    Baldus, C. D.
    Fransecky, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 139 - 139
  • [9] Cabergoline as a First-Line Treatment in Newly Diagnosed Macroprolactinomas
    N. Pontikides
    G.E. Krassas
    E. Nikopoulou
    Th. Kaltsas
    Pituitary, 2000, 2 (4) : 277 - 281
  • [10] Newly diagnosed ovarian cancer: Which first-line treatment?
    Lorusso, Domenica
    Ceni, Valentina
    Daniele, Gennaro
    Salutari, Vanda
    Pietragalla, Antonella
    Muratore, Margherita
    Nero, Camilla
    Ciccarone, Francesca
    Scambia, Giovanni
    CANCER TREATMENT REVIEWS, 2020, 91
12345